Overview

• A participant in the Phase 2 RP-A501 trial died from complications related to capillary leak syndrome.
• The FDA placed the trial on clinical hold to review safety data.
• Rocket is undertaking a root cause analysis with emphasis on a newly introduced immune suppression agent in its pre-treatment regimen.
• Shares plunged over 60% in trading to record lows and are down about 80% year-to-date.
• The company reported $318.2 million in cash and investments, sufficient to fund operations into 2027.